What is CAR-T cell therapy, and what are the two major toxicities commonly seen?

• A. Patient T cells engineered with a chimeric antigen receptor to target cancer; toxicities: cytokine release syndrome and neurotoxicity.
• B. A vaccine that introduces tumor antigens
• C. A monoclonal antibody therapy targeting PD-1
• D. A gene editing therapy to correct mutations

Answer: (A)

CAR-T cell therapy involves taking a patient’s T cells, engineering them to express a chimeric antigen receptor that recognizes a specific cancer antigen, expanding these modified T cells, and infusing them back to attack tumor cells. The two major toxicities commonly seen are cytokine release syndrome, a systemic inflammatory response caused by large-scale cytokine release from activated CAR-T cells, and neurotoxicity (immune effector cell–associated neurotoxicity syndrome, ICANS), which can manifest as confusion, seizures, or other neurologic symptoms. Management typically includes close monitoring, tocilizumab for cytokine release syndrome, and steroids for severe neurotoxicity, with supportive care as needed. This differs from vaccines (which introduce antigens to provoke an immune response), monoclonal antibody therapies targeting PD-1, and gene-editing approaches that correct mutations.